NASDAQ:VERU

Veru - VERU Stock Forecast, Price & News

$11.50

-0.39 (-3.28%)

(As of 10/6/2022 01:00 PM ET)

Add

Compare

Today's Range: $11.32
▼
$12.27
50-Day Range: $10.22
▼
$23.78
52-Week Range: $4.34
▼
$24.55

Volume: 52,180 shs
Average Volume: 6.70 million shs
Market Capitalization: $921.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.50

Veru MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 201.6% Upside
$34.50 Price Target
Short Interest: Bearish
19.70% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$2 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.85) to ($0.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

525th out of 1,072 stocks

Pharmaceutical Preparations Industry

243rd out of 534 stocks

3.5

Analyst's Opinion

Consensus Rating
Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.50, Veru has a forecasted upside of 201.6% from its current price of $11.44.
Amount of Analyst Coverage
Veru has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
19.70% of the outstanding shares of Veru have been sold short.
Short Interest Ratio / Days to Cover
Veru has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Veru has recently increased by 4.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Veru does not currently pay a dividend.
Dividend Growth
Veru does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERU.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Veru this week, compared to 7 articles on an average week.
Search Interest
Only 83 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veru insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,004,000.00 in company stock.
Percentage Held by Insiders
23.10% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
60.55% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veru are expected to grow in the coming year, from ($0.85) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veru is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veru is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veru has a P/B Ratio of 5.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Veru (NASDAQ:VERU) Stock

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

October 1, 2022 | reuters.com

VERU.OQ - Veru Inc | Stock Price & Latest News | Reuters

September 30, 2022 | investorplace.com

7 Long-Term Stocks to Buy to Tap Into a Hidden Bull Market - InvestorPlace

September 28, 2022 | americanbankingnews.com

Veru (NASDAQ:VERU) Trading 4.4% Higher

September 23, 2022 | finance.yahoo.com

Institutional owners may ignore Veru Inc.'s (NASDAQ:VERU) recent US$360m market cap decline as longer-term profits stay in the green

September 21, 2022 | globenewswire.com

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022 - GlobeNewswire

September 21, 2022 | finance.yahoo.com

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

September 20, 2022 | benzinga.com

Veru Whale Trades Spotted - Veru (NASDAQ:VERU) - Benzinga

September 20, 2022 | marketwatch.com

Veru Shares Drop 20% After FDA Reschedules Covid Drug Meeting Date - MarketWatch

September 19, 2022 | benzinga.com

Veru Announces FDA Has Rescheduled The Meeting Date To Nov. 9 For The Advisory Committee To Review Emergency Use Authorization For Sabizabulin For Hospitalized COVID-19 Patients At High Risk For Acute Respiratory Distress Syndrome; No Chan - Benzinga

September 19, 2022 | globenewswire.com

Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome - GlobeNewswire

September 19, 2022 | streetinsider.com

September 19, 2022 | finance.yahoo.com

September 19, 2022 | seekingalpha.com

VERU stock falls as FDA postponed AdCom meeting for COVID-19 therapy (NASDAQ:VERU) - Seeking Alpha

September 19, 2022 | finance.yahoo.com

September 14, 2022 | proactiveinvestors.com

Valeo Pharma enters into Canadian commercial services agreement with Veru for sabizabulin in COVID-19 treatment - Proactive Investors USA

September 13, 2022 | seekingalpha.com

Veru Stock: Stable Business And Growth Opportunities - Seeking Alpha

September 12, 2022 | proactiveinvestors.com

Todos Medical partner NLC Pharma assigns IP for Tollovir, Tollovid, and TolloTest to joint venture 3CL Pharma - Proactive Investors USA

September 12, 2022 | finance.yahoo.com

Contraceptives Global Market Report 2022 - Yahoo Finance

September 11, 2022 | realmoney.thestreet.com

Bad News Beset This Biotech, but I See a Boost Ahead - RealMoney

September 11, 2022 | benzinga.com

This Is What Whales Are Betting On Veru

September 8, 2022 | benzinga.com

Veru (NASDAQ:VERU) – FDA Schedules Adcomm For Veru's Cancer Drug Repurposed For COVID-19 - Benzinga

September 8, 2022 | seekingalpha.com

Veru Stock: A Very Complicated Tale (NASDAQ:VERU) - Seeking Alpha

September 8, 2022 | seekingalpha.com

Veru Inc.: A Very Complicated Tale

September 8, 2022 | msn.com

Police schemes set up in seven Bedfordshire schools to support pupils at risk of 'exploitation'

September 8, 2022 | finance.yahoo.com

FDA Schedules Adcomm For Veru's Cancer Drug Repurposed For COVID-19

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings: 12/02/2021
Today: 10/06/2022
Next Earnings (Estimated): 12/01/2022
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Sector: Medical
Current Symbol: NASDAQ:VERU
CUSIP: 31446210
CIK: 863894
Web: www.veruhealthcare.com
Phone: (305) 509-6897
Fax: 312-595-9122
Employees: 252
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.50
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +200.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $7.39 million
Net Margins: -89.77%
Pretax Margin: -90.02%
Return on Equity: -34.02%
Return on Assets: -27.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.62
Quick Ratio: 4.34

Sales & Book Value

Annual Sales: $61.26 million
Price / Sales: 15.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.91 per share
Price / Book: 6.02

Miscellaneous

Outstanding Shares: 80,150,000
Free Float: 61,633,000
Market Cap: $921.73 million
Optionable: Optionable
Beta: -0.25

Key Executives

Dr. Mitchell S. Steiner F.A.C.S (Age 61)
F.A.C.S., M.D., Chairman, Pres & CEO
Comp: $1.43M

Dr. Harry Fisch F.A.C.S. (Age 63)
M.D., Vice Chairman & Chief Corp. Officer
Comp: $648.12k

Ms. Michele Greco (Age 63)
CFO & Chief Admin. Officer
Comp: $659.62k

Dr. K. Gary Barnette Ph.D. (Age 54)
Chief Scientific Officer
Comp: $636.7k

Mr. Samuel Fisch
Exec. Director of Investor Relations & Corp. Communications

Mr. Michael J. Purvis
Exec. VP, Gen. Counsel & Corp. Strategy and Sec.

Mr. Kevin J. Gilbert CPA
J.D., Exec. VP of Corp. Devel.

Mr. Phillip Kuhn
Exec. VP of Strategy & Commercial

Dr. Domingo Rodriguez (Age 60)
Exec. VP of Clinical Operations

Mr. Gary Bird Ph.D.
Sr. VP of Quality Oversight

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings or view top-rated stocks.
What is Veru's stock price forecast for 2022?: 5 equities research analysts have issued 1-year price targets for Veru's shares. Their VERU share price forecasts range from $24.00 to $55.00. On average, they anticipate the company's stock price to reach $34.50 in the next year. This suggests a possible upside of 200.0% from the stock's current price.
View analysts price targets for VERU or view top-rated stocks among Wall Street analysts.
How have VERU shares performed in 2022?: Veru's stock was trading at $5.89 on January 1st, 2022. Since then, VERU shares have increased by 95.2% and is now trading at $11.50.
View the best growth stocks for 2022 here.
When is Veru's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 1st 2022.
View our VERU earnings forecast.
How were Veru's earnings last quarter?: Veru Inc. (NASDAQ:VERU) announced its quarterly earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04. The company had revenue of $15.65 million for the quarter, compared to analysts' expectations of $18.26 million. Veru had a negative net margin of 89.77% and a negative trailing twelve-month return on equity of 34.02%. During the same quarter in the previous year, the business earned ($0.01) EPS.

What other stocks do shareholders of Veru own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).
What is Veru's stock symbol?: Veru trades on the NASDAQ under the ticker symbol "VERU."
How do I buy shares of Veru?: Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Veru's stock price today?: One share of VERU stock can currently be purchased for approximately $11.50.
How much money does Veru make?: Veru (NASDAQ:VERU) has a market capitalization of $921.73 million and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or ($0.59) on an earnings per share basis.
How many employees does Veru have?: The company employs 252 workers across the globe.
How can I contact Veru?: Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Veru - VERU Stock Forecast, Price & News

Veru MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month